Pfizer's ($PFE) Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi ($SNY), EP predicts.
As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's ($MRK) Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's ($GSK) Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.
Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013. You can also peruse the rest of EP's report by downloading it here. Questions? Comments? Let us know. -- Carly Helfand (email | Twitter)
|
The top 5 vaccines by 2020
|
|
Vaccine & Company
|
Use
|
2013 Sales (billions)
|
2020 Sales (billions)
|
CAGR 2013-20
|
|
|
Pneumococcal infection |
$3.76
|
$6.08
|
7%
|
|
|
Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B |
$1.53
|
$2.34
|
6%
|
|
|
Human papillomavirus (HPV) |
$1.83
|
$2.06
|
2%
|
|
|
Influenza |
$1.23
|
$1.82
|
6%
|
|
|
Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio |
$1.35
|
$1.72
|
4%
|
|
Courtesy of EvaluatePharma |
